secwatch / observer
8-K filed January 8, 2024, 6:59 PM ET ticker RXST CIK 0001111485
earnings confidence high sentiment positive materiality 0.85

RxSight Q4 rev ~$28.6M (+78% YoY); FY2023 rev ~$89.1M (+82%); guides FY2024 rev $128-135M

RxSight, Inc.

2023-FY EPS reported -$1.41 revenue$89,077,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RxSight, Inc. reported the fourth quarter ended December 31, 2023 results: revenue approximately $28.6 million.

Period
the fourth quarter ended December 31, 2023
Revenue
approximately $28.6 million
Result
preliminary results
Exact text from the filing
Preliminary unaudited fourth quarter 2023 revenue is expected to be approximately $28.6 million
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RxSight, Inc. reported the fiscal year ended December 31, 2023 results: revenue approximately $89.1 million.

Period
the fiscal year ended December 31, 2023
Revenue
approximately $89.1 million
Result
preliminary results
Exact text from the filing
Preliminary unaudited 2023 fiscal year revenue is expected to be approximately $89.1 million
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RxSight, Inc. reported the fiscal year ending December 31, 2024 results: revenue $128.0 million to $135.0 million. Guidance initiated.

Period
the fiscal year ending December 31, 2024
Revenue
$128.0 million to $135.0 million
Guidance
initiated
Result
guidance update
Exact text from the filing
RxSight anticipates full-year 2024 revenue of $128.0 million to $135.0 million
View on SEC.gov

Browse all earnings releases →

RxSight, Inc. filing history →

Source: SEC EDGAR
accession 0000950170-24-002636
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.